None of the 86 managers this site tracks held CRISPR Therapeutics (CRSP) in their latest 13F. Between Aug 6, 2025 and Oct 26, 2026, CRISPR Therapeutics (CRSP) insiders filed 40 Form 4 transactions: 7 sales worth $4.9M in total and no open-market purchase; 3 of the sales were under 10b5-1 plans set in advance. No Schedule 13D or 13G is on file for CRSP from the activists and large holders the site follows.
Every 13F filer's holdings of CRSP are not in yet — they come from SEC's quarterly 13F data sets. Meanwhile, the superinvestors the site tracks:
No tracked superinvestor holds CRSP in their latest 13F.
A 13F is a quarterly snapshot filed up to 45 days after quarter end; 13D/13G are filed above 5%; a Form 4 within two business days of a trade. Insider holdings are the shares each person holds directly — trusts, family and other indirect holdings are reported on lines of their own and are not added in. Codes are the SEC's: P open-market purchase, S open-market sale; M exercise, F tax withholding, A grant and G gift are routine. A 10b5-1 flag means the trade ran under a plan adopted in advance. Superinvestor names link to their full books under Investors; method notes in the manual.